(Q33936337)

30 July 2017

1 reference

title

Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? (English)

1 reference

30 July 2017

acute coronary syndrome

1 reference

1 reference

Kaul S

1

1 reference

PubMed ID

10841215

30 July 2017

Shah PK

series ordinal

2

1 reference

PubMed ID

10841215

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Journal of the American College of Cardiology

30 July 2017

1 reference

30 July 2017

35

1 reference

30 July 2017

7

1 reference

30 July 2017

1699-1712

1 reference

Low-molecular-weight heparins

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Low-molecular-weight heparins: an intriguing new twist with profound implications

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Hotline sessions of the 21st European Congress of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Myonecrosis after revascularization procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Final results of the Balloon vs Optimal Atherectomy Trial (BOAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam (FATIMA) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900648-3

7 January 2021

10.1016/S0735-1097(00)00648-3

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10841215